Amundi Sells 12,676 Shares of BioNTech SE Sponsored ADR $BNTX

Amundi trimmed its holdings in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 4.5% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 268,337 shares of the company's stock after selling 12,676 shares during the quarter. Amundi owned 0.11% of BioNTech worth $24,690,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. OneDigital Investment Advisors LLC acquired a new stake in BioNTech during the 1st quarter worth about $288,000. GAMMA Investing LLC increased its holdings in BioNTech by 5,710.8% in the first quarter. GAMMA Investing LLC now owns 53,634 shares of the company's stock worth $4,884,000 after buying an additional 52,711 shares during the last quarter. Wealth Enhancement Advisory Services LLC acquired a new position in BioNTech in the fourth quarter worth approximately $238,000. Allianz Asset Management GmbH boosted its position in BioNTech by 44.3% during the first quarter. Allianz Asset Management GmbH now owns 120,680 shares of the company's stock worth $10,989,000 after purchasing an additional 37,075 shares during the period. Finally, Cerity Partners LLC bought a new stake in BioNTech during the first quarter worth approximately $357,000. 15.52% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BNTX has been the subject of a number of recent analyst reports. Leerink Partners set a $112.00 target price on BioNTech in a research report on Monday, June 2nd. Truist Financial reaffirmed a "buy" rating and set a $155.00 target price (up previously from $151.00) on shares of BioNTech in a research report on Tuesday, June 3rd. JPMorgan Chase & Co. decreased their target price on BioNTech from $120.00 to $116.00 and set a "neutral" rating for the company in a research report on Thursday, May 22nd. Bank of America upped their target price on BioNTech from $126.00 to $134.00 and gave the stock a "buy" rating in a research report on Tuesday, August 5th. Finally, Wells Fargo & Company set a $150.00 target price on BioNTech and gave the stock an "overweight" rating in a research report on Tuesday, August 5th. Thirteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, BioNTech presently has a consensus rating of "Moderate Buy" and a consensus price target of $135.80.

BioNTech Stock Performance

Shares of BNTX traded down $7.57 during mid-day trading on Friday, hitting $96.74. The company's stock had a trading volume of 5,152,296 shares, compared to its average volume of 874,805. BioNTech SE Sponsored ADR has a one year low of $81.20 and a one year high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.48 and a current ratio of 8.61. The firm has a market capitalization of $23.26 billion, a PE ratio of -60.46 and a beta of 1.39. The stock's 50-day moving average is $108.79 and its two-hundred day moving average is $103.91.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported ($1.60) earnings per share for the quarter, missing the consensus estimate of ($1.41) by ($0.19). The business had revenue of $306.46 million during the quarter, compared to the consensus estimate of $161.26 million. BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The firm's revenue was up 102.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($3.36) earnings per share. BioNTech has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that BioNTech SE Sponsored ADR will post -3.88 EPS for the current year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.